Kymera Therapeutics, Inc.·4

Mar 3, 4:52 PM ET

Chesworth Richard 4

4 · Kymera Therapeutics, Inc. · Filed Mar 3, 2021

Insider Transaction Report

Form 4
Period: 2021-03-01
Chesworth Richard
Chief Scientific Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-03-01+60,00060,000 total
    Exercise: $48.46Exp: 2031-02-28Common Stock (60,000 underlying)
Footnotes (1)
  • [F1]The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION